logo
HHS justifies decision to stop recommending Covid shots during pregnancy with studies supporting the shots' safety

HHS justifies decision to stop recommending Covid shots during pregnancy with studies supporting the shots' safety

Politico10-06-2025
The Department of Health and Human Services is circulating a document on Capitol Hill to explain its decision to remove the Covid-19 vaccine recommendation for pregnant women — citing studies that largely found the shot is safe.
The document, which HHS sent to lawmakers days before Secretary Robert F. Kennedy Jr. announced his plan to fire the panel that advises the CDC on immunizations, says that studies have shown that women who got the vaccine during pregnancy had higher rates of various complications. And it claims that 'a number of studies in pregnant women showed higher rates of fetal loss if vaccination was received before 20 weeks of pregnancy,' footnoting a research paper on vaccination during pregnancy.
But Dr. Maria P. Velez of McGill University, the lead author of one of the studies, told POLITICO in an email that 'the results of our manuscript were misinterpreted.'
The 2023 study shows a slightly higher rate of miscarriages among women who were immunized against Covid-19 during their pregnancies. But, Velez said, that after adjusting for 'variables that can confound a crude association,' like 'age, rurality, neighbourhood income quintile, immigration status, comorbidity' and other factors that could affect the outcome, Canadian researchers found 'no association between SARS-CoV-2 vaccination and an increased risk of miscarriage.'
Raw numbers don't account for significant differences among the groups being compared — such as underlying conditions and when during pregnancy the people were vaccinated, said Katelyn Jetelina, an epidemiologist who's consulted for the Centers for Disease Control and Prevention. Scientists, including the Canadian researchers, use statistical methods to adjust for those factors, she said, which is how they determined the vaccine wasn't associated with miscarriage.
In a statement, HHS spokesperson Andrew Nixon pointed to the raw study data, which showed a slightly higher rate of miscarriage in the first half of pregnancy for women who were vaccinated against Covid compared with those who weren't.
'The underlying data speaks for itself — and it raises legitimate safety concerns,' he said. 'HHS will not ignore that evidence or downplay early pregnancy loss.'
Nixon added that HHS and the CDC encourage people to talk to their providers 'about any personal medical decision.'
Vaccine researchers and obstetricians criticized the decision to remove the recommendation for pregnant women, and researchers cited in the HHS document largely dismissed any connection between Covid vaccination and miscarriages.
'Given that COVID-19 infection during pregnancy is associated with serious maternal and neonatal morbidity, the current study can inform healthcare providers, pregnant women and those considering a pregnancy about the safety of SARS-CoV-2 vaccination in relation to miscarriage risk,' Velez and her co-authors wrote in the study. That research was based on health-system data from Ontario, Canada, and aligned with similar population studies in the U.S., Scotland and Norway.
Similarly, HHS cited an April 2022 study in its document concerning mRNA vaccination in people undergoing in-vitro fertilization, which also found no adverse effects on conception rates or on early pregnancy outcomes.
'Administration of COVID-19 mRNA vaccines was not associated with an adverse effect on stimulation or early pregnancy outcomes after IVF,' the New York City-based researchers at the Icahn School of Medicine at Mount Sinai and Mount Sinai West hospital wrote in the study. 'Our findings contribute to the growing body of evidence regarding the safety of COVID-19 vaccination in women who are trying to conceive.'
The HHS document also includes an incorrect link for that study, instead leading to a different study — also cited in HHS' document — by Israeli researchers that found the vaccine 'appears to be safe during pregnancy,' with no increase in preterm labor or in newborns with low birth weight.
That February 2022 study did note a possible increase in preterm birth rates for women vaccinated during the second trimester, and the authors suggested future investigations of outcomes based on the timing of immunization.
HHS' assertion about significant risks to pregnant women 'contradicts the bulk of published studies,' said Dr. Paul Offit, an expert who has served as an outside adviser on vaccines to the FDA and the CDC.
HHS deviated from past practice when it changed the Covid vaccine guidance last month, announcing the decision without the endorsement of an existing outside panel of expert advisers.
Dr. Steven Fleischman, president of the American College of Obstetricians and Gynecologists, told POLITICO at the time that he was disappointed by HHS' decision, and pointed to data showing that newborns can benefit from maternal antibodies from the vaccine for protection from Covid.
'In fact, growing evidence shows just how much vaccination during pregnancy protects the infant after birth, with the vast majority of hospitalized infants less than 6 months of age — those who are not yet eligible for vaccination — born to unvaccinated mothers,' Fleischman said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

More Data Cement COVID's Impact on Patients With Cancer
More Data Cement COVID's Impact on Patients With Cancer

Medscape

time15 minutes ago

  • Medscape

More Data Cement COVID's Impact on Patients With Cancer

TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

Yahoo

time34 minutes ago

  • Yahoo

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know

At Least 85 People Sickened by THC at Wisconsin Pizza Place: CDC Report
At Least 85 People Sickened by THC at Wisconsin Pizza Place: CDC Report

Epoch Times

time4 hours ago

  • Epoch Times

At Least 85 People Sickened by THC at Wisconsin Pizza Place: CDC Report

Roughly nine months after an incident at a Wisconsin pizza parlor where marijuana-infused oil was used to prepare dough, the Centers for Disease Control and Prevention (CDC) released a report detailing how dozens of customers experienced symptoms consistent with THC intoxication. The report, released on July 24, describes how at least 85 people, from ages 1–91, ate food from the restaurant in Stoughton, Wisconsin, between Oct. 22 and 24, 2024, and experienced THC sickness. The restaurant was in a building with a cooperative, or shared kitchen, that was also used by a 'state-licensed vendor who produced edible THC products.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store